

Annual General Meeting and Closing Date for Director Nominations

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: **RHY**) (**Rhythm** or the **Company**) advises that in accordance with ASX Listing Rule 3.13.1, its 2024 Annual General Meeting will be held on Wednesday, 20 November 2024 in Melbourne.

On the basis of the above meeting date, and pursuant to the ASX Listing Rules, the Company advises that the closing date for the receipt of nominations from persons wishing to be considered for election as a Director is Tuesday, 1 October 2024. Any nominations must be received in writing at the Company's registered office by 5:00pm AEST.

The materials for the Annual General Meeting will be produced and provided to shareholders in due course.

- ENDS -

Authorised for release by the Board.

For further information contact us via investor@rhythmbio.com:

Dr. David Atkins Chief Executive Officer	Mr. James Barrie Jt. Company Secretary
--	--

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood presence of CRC. The test can be used as an alternative for individuals who are unable or unwilling to participate in current screening programs.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

Directors